Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Mar;155(3):474-482.
doi: 10.1016/j.chest.2018.09.031. Epub 2018 Oct 22.

Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials

Edward J Schenck  1 , Clara Oromendia  2 , Lisa K Torres  1 , David A Berlin  1 , Augustine M K Choi  1 , Ilias I Siempos  3
Affiliations
Randomized Controlled Trial

Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials

Edward J Schenck et al. Chest. 2019 Mar.

Abstract

Background: Observational studies suggest that some patients meeting criteria for ARDS no longer fulfill the oxygenation criterion early in the course of their illness. This subphenotype of rapidly improving ARDS has not been well characterized. We attempted to assess the prevalence, characteristics, and outcomes of rapidly improving ARDS and to identify which variables are useful to predict it.

Methods: A secondary analysis was performed of patient level data from six ARDS Network randomized controlled trials. We defined rapidly improving ARDS, contrasted with ARDS > 1 day, as extubation or a Pao2 to Fio2 ratio (Pao2:Fio2) > 300 on the first study day following enrollment.

Results: The prevalence of rapidly improving ARDS was 10.5% (458 of 4,361 patients) and increased over time. Of the 1,909 patients enrolled in the three most recently published trials, 197 (10.3%) were extubated on the first study day, and 265 (13.9%) in total had rapidly improving ARDS. Patients with rapidly improving ARDS had lower baseline severity of illness and lower 60-day mortality (10.2% vs 26.3%; P < .0001) than ARDS > 1 day. Pao2:Fio2 at screening, change in Pao2:Fio2 from screening to enrollment, use of vasopressor agents, Fio2 at enrollment, and serum bilirubin levels were useful predictive variables.

Conclusions: Rapidly improving ARDS, mostly defined by early extubation, is an increasingly prevalent and distinct subphenotype, associated with better outcomes than ARDS > 1 day. Enrollment of patients with rapidly improving ARDS may negatively affect the prognostic enrichment and contribute to the failure of therapeutic trials.

Keywords: ICUs; acute lung injury; acute respiratory failure; epidemiology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of rapidly improving ARDS over time. Each circle represents an ARDS Network trial, and circle size is proportional to study sample size. Increase in prevalence of rapidly improving ARDS over time was statistically significant. ALTA = Albuterol for the Treatment of Acute Lung Injury; ALVEOLI = Assessment of Low Tidal Volume and Elevated End-expiratory Volume to Obviate Lung Injury; ARMA = Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network Low-Tidal-Volume (VT) Trial; EDEN = Early vs Delayed Enteral Nutrition; FACTT = Fluid and Catheter Treatment Trial; SAILS = Statins for Acutely Injured Lungs from Sepsis.
Figure 2
Figure 2
Kaplan-Meier curves of mortality for rapidly improving ARDS and ARDS > 1 day. Patients discharged home considered alive at 60 days. Shaded area depicts 95% pointwise CIs for each curve.
See this image and copyright information in PMC

Comment in

  • Embracing the Heterogeneity of ARDS.
    Maley JH, Thompson BT. Maley JH, et al. Chest. 2019 Mar;155(3):453-455. doi: 10.1016/j.chest.2018.11.016. Chest. 2019. PMID: 30846060 No abstract available.
  • Heterogeneity of Acute Respiratory Distress Syndrome.
    Adamos G, Gavrielatou E, Sarri K, Kokkoris S. Adamos G, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):728-730. doi: 10.1164/rccm.201906-1110RR. Am J Respir Crit Care Med. 2020. PMID: 31995400 No abstract available.

References

    1. Bellani G., Laffey J.G., Pham T. LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. - PubMed
    1. Fan E., Del Sorbo L., Goligher E.C. American Thoracic Society, European Society of Intensive Care Medicine, and Society of Critical Care Medicine. An official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(9):1253–1263. - PubMed
    1. Reade M.C., Finfer S. Sedation and delirium in the intensive care unit. N Engl J Med. 2014;370(5):444–454. - PubMed
    1. Guérin C., Reignier J., Richard J.C., PROSEVA Study Group Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. - PubMed
    1. Kor D.J., Carter R.E., Park P.K. US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A). Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS—a randomized clinical trial. JAMA. 2016;315(22):2406–2414. - PMC - PubMed

Publication types

MeSH terms